Conavi Expands Leadership Team to Support Next Phase of U.S. Commercialization
Conavi Medical (OTC:CNVIF) announced leadership changes and U.S. commercialization preparations on November 3, 2025. The company appointed Mark Quick as Chief Financial Officer to lead financial strategy and investor engagement, while current CFO Stefano Picone moves to a transitional Chief Strategy Officer role to support continuity during scale-up.
Conavi also submitted its next‑generation Novasight Hybrid IVUS/OCT intravascular imaging system to the U.S. FDA for 510(k) clearance and said it is building U.S. commercial infrastructure ahead of launch.
Conavi Medical (OTC:CNVIF) ha annunciato cambi di leadership e preparativi per la commercializzazione negli Stati Uniti il 3 novembre 2025. L'azienda ha nominato Mark Quick come Direttore Finanziario (CFO) per guidare la strategia finanziaria e l'engagement con gli investitori, mentre l'attuale CFO Stefano Picone passa a un ruolo transitorio di Direttore della Strategia per supportare la continuità durante la fase di scale-up.
Conavi ha anche presentato al FDA americano il suo sistema di imaging intravascolare di prossima generazione Novasight Hybrid IVUS/OCT per l'autorizzazione 510(k) e ha dichiarato di stare costruendo l'infrastruttura commerciale statunitense prima del lancio.
Conavi Medical (OTC:CNVIF) anunció cambios en el liderazgo y preparativos de comercialización en Estados Unidos el 3 de noviembre de 2025. La empresa nombró a Mark Quick como Director Financiero para liderar la estrategia financiera y el engagement con los inversores, mientras que el actual CFO Stefano Picone pasa a un rol transitorio de Director de Estrategia para apoyar la continuidad durante la escalada.
Conavi también presentó a la FDA de EE. UU. su sistema de imagen intravascular de próxima generación Novasight Hybrid IVUS/OCT para la aprobación 510(k) y dijo que está construyendo la infraestructura comercial en EE. UU. antes del lanzamiento.
Conavi Medical (OTC:CNVIF)는 2025년 11월 3일 미국 상용화 준비와 리더십 변화를 발표했다. 회사는 Mark Quick을 최고재무책임자(CFO)로 임명하여 재무 전략과 투자자 참여를 주도하게 하고, 현 CFO Stefano Picone은 확장 시 연속성을 지원하기 위한 전환적 전략책임자(CSO) 역할로 이동한다. 또한 차세대 Novasight Hybrid IVUS/OCT 혈관 내 영상 시스템을 미국 FDA에 510(k) 승인을 위한 제출했고 출시를 앞두고 미국 내 상용 인프라를 구축 중이라고 밝혔다.
Conavi Medical (OTC:CNVIF) a annoncé des changements de direction et des préparatifs de commercialisation aux États-Unis le 3 novembre 2025. L'entreprise a nommé Mark Quick en tant que Responsable Financier pour diriger la stratégie financière et l'engagement envers les investisseurs, tandis que l'actuel CFO Stefano Picone passe à un rôle transitoire de Directeur de la Stratégie pour soutenir la continuité pendant la montée en charge.
Conavi a également soumis son système d'imagerie intravasculaire de prochaine génération, le Novasight Hybrid IVUS/OCT, à la FDA américaine pour l'autorisation 510(k) et indique qu'elle met en place une infrastructure commerciale américaine avant le lancement.
Conavi Medical (OTC:CNVIF) gab am 3. November 2025 bekannt, dass Änderungen in der Führungsebene und Vorbereitungen für die Vermarktung in den USA stattfinden. Das Unternehmen ernannte Mark Quick zum Chief Financial Officer, um die Finanzstrategie und die Investoreneinbindung zu leiten, während der aktuelle CFO Stefano Picone in eine vorübergehende Rolle des Chief Strategy Officer wechselt, um Kontinuität während des Skalierungsprozesses zu unterstützen. Conavi hat außerdem sein Next-Generation Novasight Hybrid IVUS/OCT-Intravascular-Imaging-System der US-amerikanischen FDA für eine 510(k)-Freigabe vorgelegt und gesagt, dass es die US-Vertriebsinfrastruktur vor dem Markteintritt aufbaut.
Conavi Medical (OTC:CNVIF) أعلنت عن تغييرات في القيادة واستعدادات التسويق في الولايات المتحدة في 3 نوفمبر 2025. عيّنت الشركة Mark Quick كـمدير مالي لتولي قيادة الإستراتيجية المالية والتواصل مع المستثمرين، بينما ينتقل المدير المالي الحالي Stefano Picone إلى دور مؤقت كـرئيس استراتيجية لدعم الاستمرارية أثناء التوسع. كما قدّمت Conavi أيضًا نظام التصوير داخل الأوعية الدموية من الجيل التالي Novasight Hybrid IVUS/OCT لهيئة الغذاء والدواء الأمريكية (FDA) لطلب الموافقة 510(k)، وقالت إنها تبني بنية تحتية تجارية في الولايات المتحدة قبل الإطلاق.
- Submitted next‑generation Novasight to FDA for 510(k) on Nov 3, 2025
- Appointed Mark Quick as CFO to lead U.S. financial and capital‑markets strategy
- Retained Stefano Picone in transitional Chief Strategy Officer role for continuity
- None.
- Mark Quick Appointed Chief Financial Officer, Bringing Extensive Public Company Capital Markets Expertise -
- Current CFO, Stefano Picone, will take on a Transitional Strategic Role to Support Leadership Continuity During Growth Phase -
- Leadership additions follow submission of next-generation Novasight™ to the FDA for 510(k) clearance -
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced strategic leadership changes aligned to the Company’s planned commercial launch and expansion in the United States.
Conavi has submitted its next generation Novasight Hybrid IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration (FDA) for 510(k) clearance, and is actively building the infrastructure required to support a successful U.S. launch in the largest market for intravascular imaging globally.
As part of these preparations, Conavi has appointed Mark Quick as Chief Financial Officer, bringing strong capital-markets expertise from senior roles at publicly traded life sciences and medtech companies. He will oversee financial strategy and investor engagement as Conavi prepares for launch in the United States.
Stefano Picone will take on a transitional strategic role with the Company as the Chief Strategy Officer. Having successfully guided Conavi through its go-public transaction, first public equity financing, and organizational scale-up, Mr. Picone now shifts focus to strategic execution and ensuring continuity as the Company advances through this commercial scale-up period.
“We are entering a very exciting chapter for Conavi as we prepare for broader U.S. adoption of our hybrid imaging platform,” said Thomas Looby, Chief Executive Officer of Conavi Medical. “Mark brings the ideal financial and strategic mindset to help guide our U.S. launch and expand our presence in the capital markets. Stefano’s leadership over the past decade has been instrumental in establishing the corporate foundation we stand on today, and we are grateful for his significant financial stewardship and continued support as we execute on Conavi’s long-term growth and value-creation strategy. With these leadership enhancements and U.S. expansion activities advancing, we are confident we have the right team, capabilities, and focus in place to deliver success in the United States and create long-term value for shareholders.”
“Conavi has a differentiated and highly compelling technology platform,” said Mark Quick, Chief Financial Officer of Conavi Medical. “I’m excited to join at this stage of growth and look forward to working with the team to advance a strong financial, operational, and capital markets strategy as the Company prepares for commercialization.”
Mark Quick — Chief Financial Officer
Mr. Quick is a seasoned finance executive with more than 20 years of experience in the medical technology and life sciences sectors. Prior to joining Conavi, he held senior financial leadership roles with publicly traded companies on Nasdaq, where he led capital markets strategy, budgeting and forecasting, financial reporting, and corporate development initiatives. Earlier in his career, Mr. Quick served as a sell-side equity research analyst at Canaccord Genuity, where he covered the medical device industry. Mr. Quick holds a Bachelor of Science in Mechanical Engineering from the University of Massachusetts, Amherst, and an International Master of Business Administration from the University of South Carolina.
About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit conavi.com.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to transitions in the Company’s strategic leadership, Conavi’s plans for the commercialization of its Novasight Hybrid™ System and expected FDA clearance and the commercial launch of next generation Novasight in the U.S. and other U.S. expansion activities.
These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and in the final short form prospectus of Conavi dated April 15, 2025 (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Contact:
Investors: Christina Cameron, IR@conavi.com
FAQ
What did Conavi (CNVIF) announce on November 3, 2025 about leadership?
Has Conavi (CNVIF) received FDA clearance for the next‑generation Novasight system?
What will Conavi CFO Mark Quick focus on after his appointment?
Does the November 3, 2025 announcement include U.S. commercialization plans for Conavi (CNVIF)?
Why is Stefano Picone shifting roles at Conavi (CNVIF)?
